Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 7/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.47 |
| ▸ | MPL | P40238 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888623 | 0.84 | FEN1 (0.46) | FEN1ALOX5APMPLKIF11APP | |
| SCHEMBL1658180 | 0.84 | FEN1 (0.47) | FEN1ALOX5APCYP11B2CYP11B1MPL | |
| SCHEMBL1893696 | 0.81 | FEN1 (0.47) | FEN1ALOX5APMPLKIF11APP | |
| SCHEMBL1887973 | 0.78 | CYP11B2 (0.50) | FEN1ALOX5APCYP11B2CYP11B1MPL | |
| SCHEMBL1890443 | 0.77 | FEN1 (0.44) | FEN1ALOX5APCYP11B2CYP11B1MPL | |
| SCHEMBL1891048 | 0.75 | FEN1 (0.49) | FEN1ALOX5APMPLKIF11APP | |
| SCHEMBL1888242 | 0.75 | FEN1 (0.49) | FEN1ALOX5APMPLKIF11APP | |
| SCHEMBL1893971 | 0.73 | FEN1 (0.44) | FEN1ALOX5APMPLKIF11APP | |
| SCHEMBL23255324 | 0.69 | CYP11B2 (0.50) | FEN1ALOX5APCYP11B2CYP11B1MPL | |
| SCHEMBL1886975 | 0.68 | FEN1 (0.47) | FEN1ALOX5APMPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | claimed |
| CN-101970406-A | Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH AS | 2011-02-09 | — | — | CN | claimed |
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| CN-101970406-A | Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH AS | 2011-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | FEN1 4851/4885ALOX5AP 2582/4885CYP11B2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.